S-1: Onconetix Files for $25 Million Equity Line of Credit with Keystone Capital Partners

Onconetix, Inc. has filed a registration statement for the potential sale of up to 6,250,000 shares of common stock through an equity line of credit (ELOC) with Keystone Capital Partners, aiming to raise up to $25 million.

Summary

• Onconetix, Inc., a commercial stage biotechnology company, has filed a Form S-1 registration statement with the SEC.
• The filing pertains to the offer and sale of up to 6,250,000 shares of common stock by Keystone Capital Partners, LLC.
• These shares may be issued to Keystone under a Common Stock ELOC Purchase Agreement, establishing an equity line of credit.
• Onconetix may receive up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement.
• The actual proceeds may be less depending on the number of shares sold and the price at which they are sold.
• Onconetix will not receive any proceeds from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus.
• The company intends to use the net proceeds for general corporate and working capital purposes.
• The company has paid all of the registration expenses incurred in connection with the registration of the shares.
• The purchase price per share will fluctuate based on the market price of Onconetix's shares at the time of sale to Keystone.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol ONCO.
• The last reported sale price of the company's common stock on The Nasdaq Capital Market on October 30, 2024 was $2.96 per share.
• The company is registering the shares on behalf of the Selling Stockholder, to be offered and sold by it from time to time.
• The company may amend or supplement this prospectus from time to time by filing amendments or supplements as required.

Sentiment

Score: 4

Explanation: The document outlines a necessary but potentially dilutive financing strategy. While securing funding is positive, the terms and the company's financial situation raise concerns.

Positives

• The ELOC Purchase Agreement provides Onconetix with a potential source of funding up to $25.0 million.
• The company has flexibility in determining the timing and amount of sales of common stock to Keystone.
• The company has obtained stockholder approval to issue shares to Keystone in excess of the Exchange Cap.
• The company retains control over the use of proceeds from the sale of common stock.

Negatives

• The company will not receive any proceeds from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus.
• The actual proceeds from Keystone may be less than $25.0 million depending on the number of shares sold and the price at which they are sold.
• The purchase price per share will fluctuate based on the market price of Onconetix's shares at the time of sale to Keystone.
• Sales of common stock to Keystone could cause dilution and may impact the company's stock price.
• The company's ability to access the full amount available under the ELOC Purchase Agreement is not guaranteed.
• Keystone will pay less than the then-prevailing market price for the company's Common Stock, which could cause the price of the company's Common Stock to decline.
• The company may use proceeds from sales of its Common Stock made pursuant to the ELOC Purchase Agreement in ways with which you may not agree or in ways which may not yield a significant return.

Risks

• The actual number of shares sold under the ELOC Purchase Agreement and the resulting gross proceeds are uncertain.
• The company may not have access to the full amount available under the ELOC Purchase Agreement.
• The purchase price of the common stock will fluctuate based on market prices, potentially leading to a decline in the stock price.
• Future sales of common stock could cause the market price of the shares to drop significantly.
• The company's use of proceeds may not yield a significant return.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on third parties, including Labcorp, to develop, market, distribute and sell its products.
• The company's current liabilities are significant, and if those to whom the company owes accounts payable, such as Veru, IQVIA or other creditors or vendors, were to demand payment, the company would be unable to pay.

Future Outlook

The company expects expenses to increase substantially as it commercializes Proclarix, hires additional personnel, operates as a public company, and protects its intellectual property portfolio. The company expects to generate revenue from sales of Proclarix by 2025.

Industry Context

This type of financing is common for small-cap biotechnology companies seeking to fund ongoing operations and development programs. The ELOC provides flexibility but can also lead to stock dilution.

Comparison to Industry Standards

• Comparable companies often utilize equity lines of credit to raise capital, but the terms and conditions vary widely.
• The discount to market price offered to Keystone is within the typical range for ELOC agreements.
• The potential dilution impact needs to be carefully considered in comparison to other financing options.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees' job security is uncertain given the company's financial situation.
• The company's ability to continue operations and develop its products is dependent on securing additional funding.
• Creditors face the risk of non-payment if the company is unable to raise additional capital.

Next Steps

• The company will seek to commercialize Proclarix.
• The company will explore strategic alternatives to monetize ENTADFI, such as a potential sale of the ENTADFI assets.
• The company will attempt to secure additional required funding through equity or debt financings if available.

Key Dates

Keywords

ELOC, equity line of credit, Keystone Capital Partners, common stock, registration statement, financing, Onconetix, shares